GENSCRIPT-BIOTECH
GenScript Biotech Europe BV announced that it has obtained CE marking for its SARS-CoV-2 diagnostic products to be sold as an in vitro diagnostic (“IVD”). Among these products is the novel cPassTM – SARS-CoV-2 Surrogate Virus Neutralization Test (sVNT) Kit which detects the presence of neutralizing antibodies in an hour and does not require live biological materials or biosafety containment for testing. This is a major advance in understanding the epidemiology of the disease and if individuals have developed neutralizing antibodies that may confer immunity.
cPassTM
- SARS-CoV-2 Surrogate Virus Neutralization test kit
The surrogate Virus Neutralization test kit is the result of an exclusive co-development agreement between Dr. Linfa Wang at Duke –NUS Medical School in Singapore, GenScript Biotech Corporation, and the Diagnostics Development Hub (DxD) at Singapore’s Agency for Science Technology and Research (A*STAR). Dr. Linfa Wang, a virologist, epidemiologist, and Director of the Emerging Infectious Disease program at Duke-NUS Medical School is one of the world’s leading experts on emerging zoonotic viruses. Dr. Wang serves on multiple World Health Organization (WHO) committees focused on COVID-19 and is the principal investigator of the collaboration.
GenScript went through the proof of concept research, product design, development, and optimization, working with Dr. Wang and the A*STAR team. GenScript now plays a central role in the commercialization process using its global network and manufacturing capabilities.
Dr. Wang said, "The cPass™Test Kit can be used for contact tracing, reservoir or intermediate animal tracking, assessment of herd immunity, the longevity of protective immunity and efficacy of different vaccine candidates. It does not require a biosafety containment facility, which makes it immediately accessible to the global community, including many developing nations".
"Acquiring the CE-IVD mark expands the market opportunity for our detection kits in the EU and other major international markets," said Patrick Liu, President of GenScript Biotech Europe BV. "I hope cPass™Test Kit will play a critical role in the global efforts of overcoming the pandemic.”
Together with the other CE-IVD tests GenScript offers including qRT-PCR detection kits and IgG & IgM serological testing kits, one can monitor the complete infection history of a person, from initial infection through the different stages of infection to the point of monitoring neutralizing antibodies as an indicator of future immunity against the virus.
About GenScript
GenScript is a global biotechnology group providing gene, peptide, protein, CRISPR, and antibodies to scientists in more than 100 countries. Since its founding in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science and translational biomedical research, as well as early-stage pharmaceutical development. With a mission to improve the health of mankind and nature through biotechnology, the company has developed the best-in-class capacity and capability for producing biological reagents.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005189/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Citigroup Announces €1.75 Billion Redemption of 1.250% Fixed Rate/Floating Rate Notes Due 20261.7.2025 14:30:00 CEST | Press release
Citigroup Inc. is announcing the redemption, in whole, constituting €1,750,000,000 of its 1.250% Fixed Rate/Floating Rate Notes due 2026 (the “notes”) (ISIN: XS2167003685). The redemption date for the notes is July 6, 2025 (the “redemption date”). The cash redemption price for the notes payable on the redemption date will equal par plus accrued and unpaid interest, to but excluding, the redemption date and will be paid on July 7, 2025, the next succeeding business day after the redemption date. The redemption announced today is consistent with Citigroup's liability management strategy and reflects its ongoing efforts to enhance the efficiency of its funding and capital structure. Citigroup will continue to consider opportunities to redeem or repurchase securities, based on several factors, including without limitation, the economic value, regulatory changes, potential impact on Citigroup's net interest margin and borrowing costs, the overall remaining tenor of Citigroup's debt portfoli
LevelBlue to Acquire Trustwave, Becoming Largest Pure-Play Managed Security Services Provider1.7.2025 14:00:00 CEST | Press release
LevelBlue Strengthens Market-Leading Managed Detection and Response Services with Advanced AI Capabilities, While Adding Prestigious FedRAMP and StateRAMP Authorizations LevelBlue, a global leader in cloud-based, AI-driven managed security services (MSS), has signed a definitive agreement to acquire Trustwave, a global provider of cybersecurity and managed detection and response (MDR) services from the MC2 Security Fund (MC2), a private equity fund sponsored by The Chertoff Group, an internationally recognized security and growth advisory firm. This strategic acquisition complements LevelBlue’s recent agreement to acquire Aon’s cybersecurity consulting business, formerly known as Stroz Friedberg, and further strengthens the company’s market leadership, uniting two leading Managed Security Service Providers (MSSPs) to deliver unparalleled cybersecurity outcomes through a comprehensive and expanded suite of services designed to stay ahead of the rapidly evolving threat landscape. The acq
Vertex Announces European Commission Approval of ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis1.7.2025 13:34:00 CEST | Press release
- ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for this medicine in the world -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride, demonstrating greater improvement in CFTR function -- Approximately 31,000 people with CF in the EU are now eligible for this new highly effective modulator therapy - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Thousands of people with CF across the EU may now benefit from t
LTIMindtree Launches GCC-as-a-Service1.7.2025 11:30:00 CEST | Press release
An integrated, AI-powered offering with deep industry expertise to drive growth and transformation LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company today introduced its GCC-as-a-Service. The services cater to organizations that may want to set up GCCs, scale their existing ones to optimize costs and create added value. The catalogue covers a spectrum of Build, Operate, Transform and Transfer services, offering clients the option to pick and choose what they require. GCC-as-a-Service commercials are designed on a per-seat or per service basis to ensure cost optimization and value realization. LTIMindtree’s Talent Solutions, part of our Build Services enables clients efficiently onboard business-ready talent from day one through its in-house AI-powered talent acquisition ecosystem. As a part of Transform Services, the Company provides industry specific offerings; technological solutions and frameworks that lead to acceleration of value re
Network Failures Cost $5M A Year for More Than a Quarter of Global Businesses, According to Expereo1.7.2025 10:00:00 CEST | Press release
Half of global businesses have been forced to urgently re-evaluate their tech infrastructure following a wave of high-profile IT outages Network instability is taking a serious toll on global businesses, with over a quarter (28%) reporting revenue losses of up to $5 million due to network outages or poor performance. Alarmingly, an additional 23% have experienced losses exceeding $5 million. These findings come from an IDC InfoBrief commissioned by Expereo, titled “Enterprise Horizons 2025: Technology Leaders Priorities: Achieving Digital Agility.” Following a series of high-profile IT disruptions over the past year, ranging from cybersecurity breaches to connectivity failures, nearly half (49%) of global businesses have been compelled to re-evaluate their technology infrastructure, and 40% of global tech leaders say it’s caused networking and connectivity to rise higher up the C-suite agenda. Perhaps as a result, networking/connectivity now comes out on top in terms of the technologie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom